Characterization of on-target adverse events caused by TRK inhibitor therapy
- 14 May 2020
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 31 (9), 1207-1215
- https://doi.org/10.1016/j.annonc.2020.05.006
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
This publication has 33 references indexed in Scilit:
- Management of neurogenic orthostatic hypotension: an updateThe Lancet Neurology, 2008
- Appetite Enhancement and Weight Gain by Peripheral Administration of TrkB Agonists in Non-Human PrimatesPLOS ONE, 2008
- Phenotype of cerebellar glutamatergic neurons is altered in stargazer mutant mice lacking brain‐derived neurotrophic factor mRNA expressionJournal of Comparative Neurology, 2004
- A de novo mutation affecting human TrkB associated with severe obesity and developmental delayNature Neuroscience, 2004
- Mutations in the TRKA/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosisNature Genetics, 1996
- The Trk family of neurotrophin receptorsJournal of Neurobiology, 1994
- Functions of the neurotrophins during nervous system development: What the knockouts are teaching usCell, 1994
- Severe sensory and sympathetic neuropathies in mice carrying a disrupted Trk/NGF receptor geneNature, 1994
- Targeted disruption of the trkB neurotrophin receptor gene results in nervous system lesions and neonatal deathCell, 1993
- Mineralocorticoid-Induced Hypertension in Patients with Orthostatic HypotensionNew England Journal of Medicine, 1979